5 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 4 with minor changes only.
Primary completion pushed from Jun 30, 2026 to Dec 30, 2026
Also in this update: Trial sites expanded: 10 → 14 locations
Shanghai Henlius BiotechPhase 1 NCT06115642 Registry history of NCT06115642 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 81 → 84 locations
Shanghai Henlius BiotechPhase 1 NCT07477587 Registry history of NCT07477587 on ClinicalTrials.gov (opens the registry)
Start date pushed from Nov 5, 2026 to Nov 15, 2026
And 1 more change in the last 30 days
Shanghai Henlius BiotechPhase 1 NCT07776132 Registry history of NCT07776132 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Feb 2022); last known: Not Yet Recruiting
Shanghai Henlius BiotechPhase 2 NCT05239650 Registry history of NCT05239650 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Active, Not Recruiting
Shanghai Henlius BiotechPhase 2 NCT05513573 Registry history of NCT05513573 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-08 | NCT07865910 A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for… | Phase 2/3 | Not Yet Recruiting |
| Early Phase 1 | 1 | |
| Phase 1 | 19 | |
| Phase 1/2 | 2 | |
| Phase 2 | 19 | |
| Phase 2/3 | 6 | |
| Phase 3 | 8 |
Lung Cancer (16) · Non-Small Cell Lung Cancer (NSCLC) (12) · Breast Cancer (9) · Small Cell Lung Cancer (5) · Liver Cancer (4) · Colorectal Cancer (3) · HER2-Positive Cancer (2) · Melanoma (2) · Multiple Myeloma (2) · Triple-Negative Breast Cancer (2)